191 related articles for article (PubMed ID: 30424783)
1. Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.
Ramin C; May BJ; Roden RBS; Orellana MM; Hogan BC; McCullough MS; Petry D; Armstrong DK; Visvanathan K
Breast Cancer Res; 2018 Nov; 20(1):134. PubMed ID: 30424783
[TBL] [Abstract][Full Text] [Related]
2. Bone health management of Australian breast cancer survivors receiving hormonal therapy.
Roberts R; Miller M; O'Callaghan M; Koczwara B
Intern Med J; 2015 Nov; 45(11):1182-5. PubMed ID: 26348867
[TBL] [Abstract][Full Text] [Related]
3. Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.
Hamood R; Hamood H; Merhasin I; Keinan-Boker L
Osteoporos Int; 2019 Jan; 30(1):187-200. PubMed ID: 30413856
[TBL] [Abstract][Full Text] [Related]
4. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
Kwan ML; Yao S; Laurent CA; Roh JM; Quesenberry CP; Kushi LH; Lo JC
Breast Cancer Res Treat; 2018 Apr; 168(2):523-530. PubMed ID: 29249058
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
6. A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting.
Kwan ML; Lo JC; Laurent CA; Roh JM; Tang L; Ambrosone CB; Kushi LH; Quesenberry CP; Yao S
J Cancer Surviv; 2023 Feb; 17(1):139-149. PubMed ID: 33565036
[TBL] [Abstract][Full Text] [Related]
7. Osteopenia and osteoporosis in women with breast cancer.
Ramaswamy B; Shapiro CL
Semin Oncol; 2003 Dec; 30(6):763-75. PubMed ID: 14663777
[TBL] [Abstract][Full Text] [Related]
8. Low bone mineral density is associated with breast cancer in postmenopausal women: a case-control study.
Ferreira Poloni P; Vespoli HL; Almeida-Filho BS; Bueloni-Dias F; Nahas-Neto J; Nahas EAP
Climacteric; 2017 Oct; 20(5):491-497. PubMed ID: 28569124
[TBL] [Abstract][Full Text] [Related]
9. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
[TBL] [Abstract][Full Text] [Related]
10. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
Mincey BA; Duh MS; Thomas SK; Moyneur E; Marynchencko M; Boyce SP; Mallett D; Perez EA
Clin Breast Cancer; 2006 Jun; 7(2):127-32. PubMed ID: 16800971
[TBL] [Abstract][Full Text] [Related]
11. Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.
Yao S; Laurent CA; Roh JM; Lo J; Tang L; Hahn T; Ambrosone CB; Kushi LH; Kwan ML
Breast Cancer Res Treat; 2020 Feb; 180(1):187-195. PubMed ID: 31912328
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Majithia N; Atherton PJ; Lafky JM; Wagner-Johnston N; Olson J; Dakhil SR; Perez EA; Loprinzi CL; Hines SL
Support Care Cancer; 2016 Mar; 24(3):1219-26. PubMed ID: 26298334
[TBL] [Abstract][Full Text] [Related]
13. Osteoporotic fracture risk in women with breast cancer treated with aromatase inhibitors: a health insurance claims database study in Japan.
Taguchi T; Matsushima H; Kodama S; Okubo N; Ito T; Ludwikowska M; Fukumoto S; Matsumoto T
Expert Opin Pharmacother; 2024 Feb; 25(3):325-334. PubMed ID: 38588537
[TBL] [Abstract][Full Text] [Related]
14. Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors.
Martínez P; Galve E; Arrazubi V; Sala MÁ; Fernández S; Pérez CE; Arango JF; Torre I
Reumatol Clin (Engl Ed); 2019; 15(4):211-217. PubMed ID: 29032291
[TBL] [Abstract][Full Text] [Related]
15. Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
Chen J; Zhang X; Lu Y; Zhang T; Ouyang Z; Sun Q
Breast Cancer; 2021 May; 28(3):630-643. PubMed ID: 33387283
[TBL] [Abstract][Full Text] [Related]
16. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
Bromley SE; Matthews A; Smeeth L; Stanway S; Bhaskaran K
J Cancer Surviv; 2019 Aug; 13(4):632-640. PubMed ID: 31321612
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.
van Hellemond IEG; Smorenburg CH; Peer PGM; Swinkels ACP; Seynaeve CM; van der Sangen MJC; Kroep JR; de Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Roos WK; Linn SC; Imholz ALT; de Boer M; Tjan-Heijnen VCG;
Breast Cancer Res Treat; 2020 Apr; 180(3):675-685. PubMed ID: 32124136
[TBL] [Abstract][Full Text] [Related]
18. Disease Progression Modeling Analysis of the Change of Bone Mineral Density by Postoperative Hormone Therapies in Postmenopausal Patients With Early Breast Cancer.
Yoon S; Bae KS; Cho YS; Han S; Kim H; Lim HS
J Clin Pharmacol; 2019 Nov; 59(11):1543-1550. PubMed ID: 31172521
[TBL] [Abstract][Full Text] [Related]
19. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Tjan-Heijnen VCG; van Hellemond IEG; Peer PGM; Swinkels ACP; Smorenburg CH; van der Sangen MJC; Kroep JR; De Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Boer M; de Roos WK; Linn SC; Imholz ALT; Seynaeve CM;
Lancet Oncol; 2017 Nov; 18(11):1502-1511. PubMed ID: 29031778
[TBL] [Abstract][Full Text] [Related]
20. Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Markopoulos C; Tzoracoleftherakis E; Koukouras D; Venizelos B; Zobolas V; Misitzis J; Xepapadakis G; Gogas H
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1569-77. PubMed ID: 22552718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
